CN110951873A - Bone and sarcoma marker, application thereof and kit - Google Patents
Bone and sarcoma marker, application thereof and kit Download PDFInfo
- Publication number
- CN110951873A CN110951873A CN201911217922.7A CN201911217922A CN110951873A CN 110951873 A CN110951873 A CN 110951873A CN 201911217922 A CN201911217922 A CN 201911217922A CN 110951873 A CN110951873 A CN 110951873A
- Authority
- CN
- China
- Prior art keywords
- hoxb8
- osteosarcoma
- expression
- kit
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 title abstract description 6
- 210000000988 bone and bone Anatomy 0.000 title description 4
- 206010039491 Sarcoma Diseases 0.000 title description 2
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 105
- 102100029423 Homeobox protein Hox-B8 Human genes 0.000 claims abstract description 82
- 101000988994 Homo sapiens Homeobox protein Hox-B8 Proteins 0.000 claims abstract description 82
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 238000004393 prognosis Methods 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000090 biomarker Substances 0.000 claims abstract description 5
- 101150089759 HOXB8 gene Proteins 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 16
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000004055 small Interfering RNA Substances 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 abstract description 25
- 230000009401 metastasis Effects 0.000 abstract description 25
- 210000004072 lung Anatomy 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000002626 targeted therapy Methods 0.000 abstract description 2
- 238000013399 early diagnosis Methods 0.000 abstract 2
- 239000003596 drug target Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000003197 gene knockdown Methods 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000013115 immunohistochemical detection Methods 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 239000000439 tumor marker Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108700005087 Homeobox Genes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150033506 HOX gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an osteosarcoma marker HOXB8 and application thereof. HOXB8 is significantly and highly expressed in osteosarcoma tissues, the expression level of the HOXB8 is significantly related to clinical grading, and the expression level of the HOXB8 is highest in osteosarcoma with lung metastasis; the reduction of HOXB8 expression can inhibit the growth of osteosarcoma cells, suggesting that HOXB8 can be the target of osteosarcoma treatment. The invention comprises the application of the HOXB8 protein in preparing a kit or a medicament with the following functions: (1) as a novel marker for osteosarcoma for early diagnosis and prognosis, including grading; (2) can be used as drug target to inhibit the growth of osteosarcoma. The invention provides a new idea for osteosarcoma treatment by using the HOXB8 protein as a biomarker and a targeted therapy, also provides an auxiliary detection index for early diagnosis and prognosis judgment, and has important clinical application value.
Description
Technical Field
The invention belongs to the technical field of biological medicines. Relates to a tissue tumor marker related to osteosarcoma and application thereof.
Background
The osteosarcoma is the most common primary bone malignant tumor, the osteosarcoma is the most common primary malignant bone tumor of teenagers, comprehensive treatment combining surgery and new adjuvant chemotherapy can cure about 60% of patients, 40% of patients with the osteosarcoma have far metastasis treatment failure, particularly lung metastasis is the main cause of death of the osteosarcoma, a lung metastasis focus is insensitive to the existing chemotherapeutic drugs, the targeted drugs do not have breakthrough progress, 5-year survival rate of the patients with the lung metastasis is lower than 20%, the pulmonary sarcoma pulmonary metastasis becomes a bottleneck restricting prognosis improvement, so that the curative effect is not long in thirty years, how to effectively discover and inhibit the pulmonary metastasis of the osteosarcoma is a clinical problem to be solved, a series of discussions on the onset of the osteosarcoma and the like exist in the past, the defects of low sensitivity and low specificity of commonly-used markers are found, the molecular limitation mechanism of the pulmonary metastasis of the osteosarcoma is deeply researched and clarified, a new osteosarcoma prevention and treatment target is found and can effectively intervene in controlling the pulmonary metastasis of the osteosarcoma, the further improvement of the curative effect of the osteosarcoma is the lung metastasis of the low grade of the benign metastatic tumor, the malignant tumor is represented by the international grade of the international grade T No. 7, the international grade No. 7. the international grade No.1, the international grade No. 7. the benign metastatic tumor is represented by the international grade No.1, the international grade No. 8. the international grade of the international grade No.1, the international grade of the intraspecific malignant tumor, the international grade No.1, the international grade of the intraspecific malignant tumor is represented by the international grade No.1, the international grade of the international grade No.1, the international grade No. 8. the international grade of the intraspecific malignant tumor is represented by the international grade of the intraspecific malignant tumor, the international grade No. 1.
The most common part of the hematogenous metastasis of osteosarcoma is the lung, so postoperative follow-up chest imaging examination of osteosarcoma patients is extremely important. Once lung metastasis occurs, the prognosis of the patient is poor and the survival rate is far low. However, even so, for patients with lung metastasis, surgical resection of metastasis is still claimed at present, and conventional chemotherapy is required before and after resection of metastasis, so that development of a new targeted therapeutic approach is an urgent need for osteosarcoma prevention and treatment. The tumor marker kit is used for detecting the molecular pathological changes of patients, and early screening or auxiliary diagnosis is realized, so that effective tumor markers need to be found. Specific treatment by new means such as gene therapy, immunotherapy, molecular targeted therapy requires finding specific markers for osteosarcoma cells.
The HOX (Homeobox) gene is a development related gene, and the encoded protein plays a role in regulating transcription factors in the process of embryonic development. It was first discovered to play an important role in the embryonic development of drosophila melanogaster. HOXB8(NCBI accession No. NM-024016.4, GeneID:3218) is one of the HOX gene family members and is located on chromosome 17. A recent study has shown that HOXB8 is aberrantly expressed in a variety of tumor cells and is associated with tumor development and chemotherapeutic effects. The research finds that HOXB8 in the osteosarcoma patient is abnormally high expressed, the expression is more obvious along with the increase of the level of the osteosarcoma, and the HOXB8 high expression is obviously related to the metastasis and poor prognosis of the osteosarcoma patient; by constructing a HOXB8 lentiviral vector, a HOXB8 knockdown cell model is established, and the influence of the HOXB8 knockdown cell model on the growth and transfer of osteosarcoma cells is researched. Aims at discussing the relation between the expression of HOXB8 and the generation and transfer of osteosarcoma and lays a foundation for further researching the targeted therapy and regulation mechanism of HOXB8 on osteosarcoma. And knockdown of HOXB8 expression with shRNA significantly inhibited osteosarcoma growth. The application shows that the HOXB8 can be used as a biological marker and a therapeutic target of osteosarcoma and is used for auxiliary diagnosis, curative effect detection, prognosis judgment and the like of osteosarcoma. Through retrieval, no relevant report and patent application aiming at HOXB8 in osteosarcoma exists at present.
HOXB8 sequence information:
disclosure of Invention
The invention aims to screen out a tumor marker related to osteosarcoma, wherein the marker is a DNA sequence HOXB8 gene. The sequence can also be applied to auxiliary diagnosis, metastasis prediction and prognosis judgment and treatment of osteosarcoma.
The kit for auxiliary diagnosis, curative effect prediction and prognosis of osteosarcoma comprises a specific primer of a HOXB8 gene, an upstream primer and a downstream primer of the specific primer of the HOXB8 gene, wherein the sequence of the specific upstream primer of the HOXB8 gene is shown as SEQ ID No.1, and the sequence of the downstream primer of the HOXB8 gene is shown as SEQ ID No. 2.
The kit comprises a real-time fluorescent quantitative PCR detection kit and an immunohistochemical detection kit. Wherein the primers in the real-time fluorescent quantitative PCR detection kit are suitable for detecting SYBR Green. In addition, the kit also comprises a standard DNA template and a PCR reaction system, wherein the PCR reaction solution in the PCR reaction system is real-time fluorescent quantitative PCR reaction solution and further comprises fluorescent dye. The real-time fluorescent quantitative PCR reaction solution comprises dNTP, Mg2+, Taq enzyme and buffer solution, wherein the fluorescent dye is SYBR Green II, and the Taq enzyme is hot-start enzyme. The immunohistochemical detection kit comprises a standard substance control, an HOXB8 antibody and a reagent related to immunohistochemical detection.
The reference value level is the expression level of the HOXB8 gene in normal cells, i.e. normal human osteoblasts, of the same line as the test cells and free from canceration. The assay cell is known or suspected to comprise a tumor cell.
The inventor finds that the primer for detecting the HOXB8 has good specificity, has high accuracy for diagnosing osteosarcoma, finds a novel gene which can be used as a tumor marker, has high expression in tumor cells and tissues, has the expression quantity remarkably related to clinical pathological parameters of tumors, and shows that the HOXB8 is a specific tumor marker. The present invention has been completed based on this finding.
In order to verify the diagnostic effectiveness of the invention, the invention verifies the expression characteristics of the cancer marker and the influence of the expression characteristics on the growth function of osteosarcoma cells by adopting a RT-PCR (reverse transcription-polymerase chain reaction), immunohistochemistry and gene knock-down method. The experimental method mainly comprises the following parts:
1. gene expression differences were verified in osteosarcoma and paracarcinoma samples using RT-PCR: extracting total RNA of osteosarcoma and paratissue thereof; designing a primer, and carrying out PCR reaction; HOXB8 expression in osteosarcoma tissues was significantly higher than in paracarcinoma tissues.
2. The immunohistochemistry technology is applied to 60 osteosarcoma sample sections for dyeing to verify that the expression difference of the HOXB8 in osteosarcoma patients with different degrees of malignancy is as follows: the samples are osteosarcomas with different degrees of malignancy collected clinically, and the survival curve of osteosarcoma patients is analyzed according to the HOXB8 staining score and clinical follow-up data, so that the prognosis of the patients with high expression HOXB8 is worse than that of the patients with low expression, and the expression of HOXB8 in the patients with lung metastasis is higher than that of the patients without lung metastasis.
2. The influence of the gene on the growth and transfer functions of osteosarcoma cells is verified at a cellular level: expressing shRNA knock-down gene; the effect of HOXB8 on cell growth was verified. The result shows that the osteosarcoma cell growth capacity of knocking down the HOXB8 gene is obviously reduced.
3. The influence of the gene on the growth function of osteosarcoma is verified at the global level: the HOXB8 gene is knocked down, and is transplanted to the tibia of a nude mouse in situ after verification, so that the influence of the gene on the growth and transfer of osteosarcoma is verified. The result shows that the osteosarcoma growth and transfer capability of knocking down the HOXB8 gene are obviously reduced.
The inventor finds that the primer for detecting the HOXB8 has good specificity and has high accuracy for diagnosing osteosarcoma. Therefore, the invention provides a kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of osteosarcoma.
The kit for auxiliary diagnosis, curative effect prediction and prognosis of osteosarcoma comprises a specific primer of a HOXB8 gene, an upstream primer and a downstream primer of the specific primer of the HOXB8 gene, wherein the sequence of the specific upstream primer of the HOXB8 gene is shown as SEQ ID No.1, and the sequence of the downstream primer of the HOXB8 gene is shown as SEQ ID No. 2.
The kit comprises a real-time fluorescent quantitative PCR detection kit and an immunohistochemical detection kit. Wherein the primers in the real-time fluorescent quantitative PCR detection kit are suitable for detecting SYBRGreen. In addition, the kit also comprises a standard DNA template and a PCR reaction system, wherein the PCR reaction solution in the PCR reaction system is real-time fluorescent quantitative PCR reaction solution and further comprises fluorescent dye. The real-time fluorescent quantitative PCR reaction solution comprises dNTP and Mg2+The fluorescent dye is SYBRGreenII, and the Taq enzyme is hot-start enzyme. The immunohistochemical detection kit comprises a standard substance control, an HOXB8 antibody and a reagent related to immunohistochemical detection. The use of the kit comprises obtaining a test sample from a tissue or cell; determining the expression level of a biomarker in the test sample; analyzing the expression level to generate a risk score, wherein the risk score can be used to provide a hierarchical diagnosis and prognosis of the subject. The test sample is fresh, frozen or paraffin-fixed embedded tissue.
The reference value level is the expression level of the HOXB8 gene in normal bone tissue.
Based on the findings of the present invention, one skilled in the art can determine:
the application of the HOXB8 gene as a biological marker of osteosarcoma is characterized in that the HOXB8 gene is highly expressed in osteosarcoma tissues.
The HOXB8 gene can be used as a detection target of a detection kit for the auxiliary diagnosis, the curative effect prediction and the prognosis judgment of osteosarcoma.
3. The reagent for detecting the expression of the HOXB8 can be used as a reagent for auxiliary diagnosis, curative effect prediction and prognosis judgment of osteosarcoma, and the reagent for detecting the expression of the HOXB8 is a probe or a primer for specifically detecting HOXB8 mRNA or an antibody specifically binding with HOXB8 protein.
4. Conventional test samples such as fresh, frozen or paraffin-fixed embedded tissue can be used for the above tests.
5. The substance for inhibiting the expression of HOXB8 can be used for preparing a medicine for treating osteosarcoma, wherein the substance for inhibiting the expression of HOXB8 is miRNA, siRNA, dsRNA or shRNA, or an over-expression plasmid vector or lentivirus containing the miRNA, siRNA, dsRNA or shRNA.
The HOXB8 protein as a target can be used for screening anti-osteosarcoma drugs.
Drawings
FIG. 1 shows the comparison of the expression level of HOXB8 in the GEO database in the normal osteoblasts and in the osteosarcoma tissues (A), and the expression level of HOXB8 in the tissues of the non-relapsed and relapsed osteosarcomas (B).
FIG. 2 is a comparison (A) of the expression levels of HOXB8 detected by RT-qPCR in clinical osteosarcoma samples and in paracancerous tissue samples, the expression level of HOXB8 in different encocking grades shown by immunohistochemistry, the expression level difference between metastatic and non-metastatic osteosarcoma (B), the relation (C) between the expression level of HOXB8 and the survival curve of osteosarcoma patients shown by immunohistochemistry, and the statistical table (D) of the staining score of HOXB8 and various clinical indexes.
FIG. 3 shows the effect of different shRNAs on osteosarcoma cell proliferation and metastatic capacity. Shows the effect of shRNA interference on the growth of nude mouse orthotopic tumor graft (C) and the difference of metastasis (D) on the number of cell growth changes (A) and invasiveness changes (B) of two tumor cell lines after the knockdown of HOXB 8.
Detailed Description
The invention is further described with reference to the following figures and examples.
Example 1 analysis of the data from the GEO database reveals the difference in expression of HOXB8 gene between osteosarcoma tissue and para-carcinoma tissue, and the relationship between HOXB8 and osteosarcoma patient recurrence.
RNA-seq sequencing data and clinical data of two groups of osteosarcoma tissue samples are downloaded by adopting a GEO standard method, and statistical software is used for making the expression difference of HOXB8 in osteosarcoma tissues and tissues beside the osteosarcoma tissues and the expression difference of HOXB8 in patients with recurrent and non-recurrent osteosarcoma.
As a result: referring to fig. 1A, analysis found that HOXB8 expression in osteosarcoma was significantly increased compared to normal osteoblasts, and fig. 1B shows that HOXB8 expression in relapsed osteosarcoma was higher than in non-relapsed patients, considering its use as an early diagnostic indicator of osteosarcoma.
Example 2: RT-qPCR verified the expression difference of the HOXB8 gene in osteosarcoma tissues and para-carcinoma tissues.
Osteosarcoma tissue was obtained by surgical excision and confirmed by pathological diagnosis by measuring the expression status of HOXB8 gene in 9 pairs of osteosarcoma tissue and paracarcinoma tissue.
First, total RNA extraction of cells was performed. All manipulations and related reagents were placed on ice for manipulation. Extracting total RNA of cells by using Trizol reagent, which comprises the following steps: total RNA extraction is prepared. Cells were directly digested with Trizol, lysed, and Trizol was added. After adding Trizol, the cells were left at room temperature for 5min to be sufficiently lysed. The mixture was centrifuged at 12000rpm at 4 ℃ for 5min using a high-speed refrigerated centrifuge, and the precipitate was discarded. Adding chloroform into 200ul chloroform/ml Trizol, shaking and mixing for 15min, and standing at room temperature for 15 min. The mixture was again centrifuged at 12000g at 4 ℃ for 15min using a high-speed refrigerated centrifuge. The upper aqueous phase was then aspirated into another centrifuge tube. 0.5ml of isopropanol Trizol is added into the isopropanol and mixed evenly, and the mixture is placed for 10min at room temperature. The mixture was centrifuged again at 12000g at 4 ℃ for 10min by using a high-speed refrigerated centrifuge, and the supernatant was discarded, and RNA was deposited on the bottom of the tube. 1ml of 75% ethanol was added, the tube was gently shaken and the pellet suspended. Centrifuging at 4 deg.C and 8000g for 5min with a high-speed refrigerated centrifuge, discarding supernatant as much as possible, air drying residual RNA on a clean bench for 3min, and adding 30ul H2O to dissolve RNA sample. The quality and concentration of RNA are determined by measuring the O.D value, and the purity of RNA can be ensured when the A260/A280 value is 1.6-1.8.
Second step, useIII cDNA was synthesized using the reverse transcription kit (Invitrogen) according to the following protocol: all manipulations and related reagents were worked on ice. Reagents were added to the PCR reaction tube at concentrations according to the instructions and finally the RNA sample was added. The reaction conditions in the PCR instrument were set as follows: the cDNA samples were obtained at 42 ℃ for 45min (reverse transcription) and at 75 ℃ for 10min (heat shock termination reaction).
And thirdly, quantitatively carrying out PCR (polymerase chain reaction) to identify the expression quantity of the HOXB8 gene, wherein the specific operation steps comprise that all operations and related reagents are put on ice for operation, the reagents and the concentration shown in the table 1 are added into a PCR reaction tube, and finally, a cDNA sample is added, reaction conditions are set in a PCR instrument, wherein the reaction conditions comprise that the temperature is 94 ℃ for pre-denaturation for 10s, the temperature is 94 ℃ for denaturation for 5s, the temperature is 60 ℃ for annealing/extension for 34s, 40 cycles are totally, β -Actin is used as a relative quantitative internal reference, and PCR primers are shown in the table 1.
Table 1 method for identifying expression quantity of HOXB8 gene by RT-PCR
Reactants | Reaction amount |
SYBR Green qPCR Master mix(2X) | 10μl |
Forward Primer(10μM) | 1μl |
Reverse Primer(10μM) | 1μl |
H2O | 7.5μl |
cDNA | 0.5μl |
Total amount of | 20μl |
TABLE 2 primer sequences for RT-PCR identification of the HOXB8 gene
Data processing and analysis: the relative expression amount of the gene is calculated by a 2-delta-Ct method.
As a result: referring to fig. 2A, we examined the mRNA expression of HOXB8 in osteosarcoma tissue and para-carcinoma tissue, found that HOXB8 mRNA was expressed in tumor tissue, and validated the database.
Example 3: by immunohistochemistry, the relationship between HOXB8 expression and overall survival of osteosarcoma patients was explored.
Placing a clinically collected osteosarcoma sample in 10% neutral buffered formalin, fixing the osteosarcoma sample for 8-24 h at normal temperature, dehydrating, slicing, adhering a slide glass with the thickness of 2 mu m, setting the temperature of the baking sheet at 65-68 ℃ for 2h, and dewaxing the xylene I and II for 12 minutes respectively, wherein the amount of a general fixing solution is 4-10 times of the volume of a tissue block; 3 minutes for each of the absolute ethyl alcohol I and the absolute ethyl alcohol II; (xylene wash) 95% ethanol for 3 minutes; 85% ethanol for 3 minutes; rinsing with tap water for 3 minutes, washing completely, soaking with 0.1% Triton x-100 for 10min, soaking with PBS for 5min × 2 times, heating EDTA antigen repairing solution to 92-98 deg.C (microwave oven middle fire for 5 min), and then low fire at 92-98 deg.C for 5min × 4 times (guaranteed temperature). Cooling to room temperature, soaking in PBS, and soaking the repaired antigen slice in tap water for 2 min. The samples were placed in endogenous peroxidase blocker 3% H2O2 (methanol) for 4 minutes at room temperature. The washing was carried out with tap water for 2 minutes and PBS buffer for 2 minutes. The sections were taken out, wiped to dry the liquid surrounding the tissue, 10% BSA blocking solution was added dropwise, and incubated at 37 ℃ for 40 minutes. Dropping primary antibody (concentration ratio, PBS is diluted by 1:50, 20ul, tissue is kept in a wet state but no liquid can be on the surface, putting the tissue into a special incubation box, taking out the tissue after overnight staying in a refrigerator at 4 ℃, taking out the tissue, washing the tissue for 3 minutes and 3 times in PBS buffer solution, wiping the liquid around the tissue, dropping secondary antibody, incubating the tissue in an incubator at 37 ℃ for 40 minutes, washing the tissue with PBS buffer solution for 3 minutes and 3 times, dropping a ready-prepared DAB color developing agent for room temperature color development, washing the tissue with tap water for 3 minutes, dyeing the tissue in hematoxylin dyeing solution for 40 seconds, washing the tissue for 1 minute, differentiating the tissue with 1% hydrochloric acid alcoholic solution for 3 seconds, rinsing with running water, dehydrating, placing the tissue in sequence in 85% ethanol, 95% ethanol for 1 minute, absolute ethanol for 2 minutes in sequence I and II, and placing the tissue in sequence in xylene.
As a result: referring to fig. 2B, immunohistochemical staining showed that HOBX8 was expressed in higher amounts in metastatic osteosarcoma than in metastatic osteosarcoma, and the expression was also increased with increasing grade. Statistical analysis revealed that HOXB8 expression had a significant correlation with survival in osteosarcoma patients, and that overall survival in patients with high HOXB8 expression was significantly lower than in patients with HOXB8 low expression, suggesting that HOXB8 is likely to have an effect in promoting cancer progression (fig. 2C). Fig. 2D shows how HOXB8 relates to various clinical indicators.
Example 4: effect of inhibition of HOXB8 expression levels using shRNA on osteosarcoma cell proliferation. (FIG. 3A)
Knockdown of the HOXB8 gene was performed using two different shrnas (shRNA sequences are shown in table 3), and the degree of down-regulation of HOXB8 expression was compared in both cases. Dividing osteosarcoma cells 143B and SJSA1 into three groups, wherein group I is a control group without gene knock-down and expression inhibitor; group II is HOXB8 shRNA1 knockdown group; group III is the HOXB8 shRNA2 knockdown group. The proliferation of the tumor cells was observed 12h, 24h, 36h, 48h, 60h and 72h after the culture under the same culture conditions.
TABLE 3 ShRNA sequences for knockdown of the HOXB8 Gene
Numbering | Name of nucleic acid sequence | Sequence of |
SEQ ID NO 3 | HOXB8 shRNA1 | AGTACGCAGACTGCAAGCTTG |
SEQ ID NO 4 | HOXB8 shRNA2 | GAGTTCCTATTTAATCCCTAT |
As a result: in both the shRNA1 and shRNA2 groups, the number of cell lines was significantly lower than the control group compared to the control group (fig. 3A). These results demonstrate that knockdown HOXB8 is capable of inhibiting the growth of osteosarcoma cell line 143B, SJSA 1.
Example 5: effect of inhibition of HOXB8 expression levels using shRNA on the ability of osteosarcoma cells to invade. (FIG. 3B)
Knockdown of the HOXB8 gene was performed using two different shrnas (shRNA sequences are shown in table 3), and the degree of down-regulation of HOXB8 expression was compared in both cases. Dividing osteosarcoma cells 143B and SJSA1 into three groups, wherein group I is a control group without gene knock-down and expression inhibitor; group II is HOXB8 shRNA1 knockdown group; group III is the HOXB8 shRNA2 knockdown group. Each group of cells was inoculated into a transwell chamber (40000 cells/well) plated with Matrigel and cultured for 24 hours, the chamber was taken out and washed with PBS, fixed with methanol, stained with 0.5% crystal violet, and the invasion of cells was observed under a microscope after washing.
Example 6: blocking osteosarcoma metastasis in vivo after inhibiting HOXB8 expression level by shRNA
143B cells obtained in the three groups of example 5 were transformed with luciferase with lentivirus at a dose of 1.5X 106The tibia of a 5-week-old female nude mouse is inoculated in situ, the first in-vivo imaging shooting is started after 1 week, the shooting is performed every 7 days later, the fluorescence intensity of a tumor part is calculated, and the experiment is ended after 5 weeks.
As a result: the fluorescence intensity of the orthotopic transplantation tumor is shown in FIG. 3C, and the fluorescence intensity of the metastasis is shown in FIG. 3D. Both HOXB8 knockdown 143B cells had significantly less tumor volume than the control cells. Osteosarcoma lung metastases also disappeared after inhibition of HOXB 8.
In combination with the above results, HOXB8 was significantly highly expressed in osteosarcoma, and the expression level in osteosarcoma with lung metastasis was higher than that in osteosarcoma without lung metastasis. And the conclusion is verified on the functional level. The high expression of the HOXB8 is reflected to have the capability of marking osteosarcoma metastasis, and the HOXB8 can be used as an osteosarcoma marker and applied to auxiliary diagnosis, curative effect prediction and prognosis judgment of osteosarcoma. In addition, the above description is only for the preferred embodiment of the present invention and should not be taken as limiting the invention, and any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
- The application of HOXB8 gene as osteosarcoma biomarker, characterized in that HOXB8 gene is highly expressed in osteosarcoma tissue.
- 2. An osteosarcoma detection kit comprises a reagent for detecting the expression of HOXB8, and is a kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of osteosarcoma.
- 3. The osteosarcoma detection kit of claim 2, wherein said reagent for detecting the expression of HOXB8 is a probe or primer for specifically detecting HOXB8 mRNA, or an antibody specifically binding to HOXB8 protein.
- 4. The detection kit as claimed in claim 3, wherein the kit comprises an upstream detection primer and a downstream detection primer, the upstream detection primer has the sequence of SEQ ID NO 1, and the downstream detection primer has the sequence of SEQ ID NO 2.
- 5. The test kit according to claim 3, which is a kit for prognosis of osteosarcoma, wherein the test sample is fresh, frozen or paraffin-fixed embedded tissue.
- 6. The application of the substance for inhibiting the expression of HOXB8 in preparing the medicine for treating osteosarcoma is that the substance for inhibiting the expression of HOXB8 is miRNA, siRNA, dsRNA or shRNA, or an over-expression plasmid vector or lentivirus containing the miRNA, siRNA, dsRNA or shRNA.
- 7. The substance that inhibits the expression of HOXB8 according to claim 6, comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
- The application of the HOXB8 protein as a target in screening anti-osteosarcoma drugs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911217922.7A CN110951873A (en) | 2019-12-03 | 2019-12-03 | Bone and sarcoma marker, application thereof and kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911217922.7A CN110951873A (en) | 2019-12-03 | 2019-12-03 | Bone and sarcoma marker, application thereof and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110951873A true CN110951873A (en) | 2020-04-03 |
Family
ID=69979440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911217922.7A Pending CN110951873A (en) | 2019-12-03 | 2019-12-03 | Bone and sarcoma marker, application thereof and kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110951873A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726181A (en) * | 2023-08-09 | 2023-09-12 | 四川省医学科学院·四川省人民医院 | Use of agent for inhibiting NAT9 gene expression |
CN117805381A (en) * | 2024-02-29 | 2024-04-02 | 首都医科大学附属北京积水潭医院 | Application of Gasderm protein family detection substance in preparation of osteosarcoma detection product |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137086A1 (en) * | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
CN105934521A (en) * | 2013-08-02 | 2016-09-07 | 纪念斯隆-凯特琳癌症中心 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition |
CN108753981A (en) * | 2018-07-31 | 2018-11-06 | 深圳大学 | Application of the quantitative detection of HOXB8 genes in colorectal cancer Index for diagnosis |
CN108949768A (en) * | 2018-04-28 | 2018-12-07 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | A kind of RAB22A-NoeFs fusion system and its application for diagnosing and/or treating osteosarcoma |
-
2019
- 2019-12-03 CN CN201911217922.7A patent/CN110951873A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137086A1 (en) * | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
CN105934521A (en) * | 2013-08-02 | 2016-09-07 | 纪念斯隆-凯特琳癌症中心 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition |
CN108949768A (en) * | 2018-04-28 | 2018-12-07 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | A kind of RAB22A-NoeFs fusion system and its application for diagnosing and/or treating osteosarcoma |
CN108753981A (en) * | 2018-07-31 | 2018-11-06 | 深圳大学 | Application of the quantitative detection of HOXB8 genes in colorectal cancer Index for diagnosis |
Non-Patent Citations (2)
Title |
---|
JIANKUO GUO ET AL.: "Knockdown of HOXB8 inhibits tumor growth and metastasis by the inactivation of Wnt/β-catenin signaling pathway in osteosarcoma", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
黄立勇 等: "miR-196和HoxB8与结直肠癌Folfox4化疗敏感性的相关研究", 《中国普外基础与临床杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116726181A (en) * | 2023-08-09 | 2023-09-12 | 四川省医学科学院·四川省人民医院 | Use of agent for inhibiting NAT9 gene expression |
CN116726181B (en) * | 2023-08-09 | 2023-10-20 | 四川省医学科学院·四川省人民医院 | Use of agent for inhibiting NAT9 gene expression |
CN117805381A (en) * | 2024-02-29 | 2024-04-02 | 首都医科大学附属北京积水潭医院 | Application of Gasderm protein family detection substance in preparation of osteosarcoma detection product |
CN117805381B (en) * | 2024-02-29 | 2024-05-28 | 首都医科大学附属北京积水潭医院 | Application of substances for detecting GASDERMIN protein family in preparation of products for detecting osteosarcoma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellone et al. | Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy | |
Tanaka et al. | Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma | |
Zhou et al. | miR‐145‐5p affects the differentiation of gastric cancer by targeting KLF5 directly | |
JP2011511634A (en) | Methods and compositions relating to cancer stem cells | |
CN108342482B (en) | Glioblastoma marker, application thereof and kit | |
Li et al. | The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis | |
CN109423517B (en) | Use of exosomes in tumor diagnosis, treatment and prognosis evaluation | |
Chiappetta et al. | FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders | |
Dai et al. | Role of miR-139 as a surrogate marker for tumor aggression in breast cancer | |
El-Shal et al. | Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer | |
Shi et al. | CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma | |
Zhang et al. | piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9 | |
CN107904311B (en) | Prostate cancer marker and application thereof | |
Xuan et al. | MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. | |
CN110951873A (en) | Bone and sarcoma marker, application thereof and kit | |
CN108660212B (en) | Application of WDR1 gene in preparation of non-small cell lung cancer treatment and detection products | |
CN103969452B (en) | The classification diagnosis kit of BAY 43-9006 personalized treatment liver cancer | |
CN108841955A (en) | Application of the C22orf41 as Pancreatic Cancer Tumor Markers object | |
Murayama et al. | miR‐144‐3p/miR‐451a promotes lymphovascular invasion through repression of PTEN/p19 in rectal neuroendocrine tumors | |
CN112641797B (en) | Target and diagnostic marker for inhibiting colorectal cancer growth and metastasis and application thereof | |
CN114182014A (en) | Target for inhibiting proliferation and metastasis of colorectal cancer and application thereof | |
CN111088357B (en) | Tumor marker for ESCC and application thereof | |
CN107022627B (en) | Application of KPNA2 gene and application of siRNA for inhibiting KPNA2 gene expression | |
CN113502329A (en) | Application of reagent for detecting adenosine receptor A2B expression level in preparation of kit for diagnosis and/or prognosis of lung adenocarcinoma | |
CN112755190A (en) | Target and diagnostic marker for inhibiting colorectal cancer growth and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200403 |
|
RJ01 | Rejection of invention patent application after publication |